In this podcast, expert clinicians will review the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in reducing low-density lipoprotein cholesterol (LDL-C) and reducing cardiovascular risk. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/cardiology/20250102/4-lipid-legends-with-your-host-dr-ronald-codario-featuring-dr-peter-toth-pcsk9-inhibition